Tag: CMA
-

All change for the UK merger regime – Except the standard of review?
Traditionally, the UK has had a two-stage decision making process for merger cases. First, there were two separate organisations, the Office of Fair Trading (OFT) and the Competition Commission (CC). The OFT would carry out the first phase review of a merger (“Phase 1”) and, if there were reasonable prospects that the merger would result…
-

UK Competition and Market Authority’s consultation on merger remedies confirms greater flexibility
The CMA’s consultation on its revised merger remedies guidance, published on 16 October 2025, confirms a more flexible approach to remedies including in Phase 1 – a trend already seen in recent CMA decisions.
-

Combination Therapies in Pharma – Removing the Antitrust Roadblock
This month, the Belgian Competition Authority (BCA) published guidance on information exchange between pharmaceutical companies in the context of the reimbursement application procedure for combination therapies. This follows a prioritisation statement adopted by the UK Competition and Markets Authority (CMA) in 2023 on the same issue and long-standing demands from the Belgian pharmaceutical industry.[1] In…
-

Private Equity and Common Ownership in Professional Rugby: Applying the Delivery Hero Standard
By Dr Beverley Williamson From time to time, the Thicket blog invites guest bloggers to write about a topic that is close to their heart. Geradin Partners is pleased to give the floor to friend of the blog Dr Bev Williamson who is an expert in the application of competition law in the sports industry.…
-

“Like ships in the night” – the Court of Appeal’s Hydrocortisone judgment vindicates CMA and brings welcome order to a procedure that had been spinning out of control
The CMA’s pharma cases have generated a lot of work for the UK’s antitrust lawyers and economists, with a good proportion of practitioners having worked on at least one of Paroxetine, Phenytoin, Liothyronine or Hydrocortisone over the past few years. Dawn raids and large fines in these pharma cases highlighted the emergence of a more…
-

The ACM’s mission to plug the “small acquisitions gap”
In line with recent developments in other countries, the ACM’s chairman Martijn Snoep has expressed a desire for new competences to review relatively small mergers (in size) that fall below the notification thresholds of the Dutch Competition Act (DCA).[1] In the ACM’s view, mergers that fall below these thresholds can nonetheless cause competition problems. In…
-

CAT’s Liothyronine judgment is notable beyond excessive pricing cases
Last week’s Liothyronine judgment in the UK’s Competition Appeal Tribunal (CAT) is essential reading for antitrust practitioners. The CAT upheld the CMA finding of an abuse of dominance but reduced the total fine from £101m to £84m. Liothyronine is one of several excessive pricing cases the CMA has brought in recent years following concerns about…
-

Antitrust and private equity – parental liability rules can allow authorities to claw back profits in UK and Europe
Private equity (PE) is in focus for antitrust authorities. In a merger control context, concerns around roll-up and keeping the bigger picture in mind occupy both Jonathan Kanter at the DOJ and Lina Khan at the FTC. My colleague Stijn Huijts covered this in his 13 June 2022 blog. Consideration of the PE angle is…
-

Phenytoin – was it worth it?
On 21 July 2022 the CMA imposed fines of £63m on Pfizer and £6.7m on Flynn in relation to the excessive pricing of the generic drug phenytoin, an anti-epilepsy drug. This comes nearly six years on from the CMA’s first infringement decision in relation to the conduct. That first decision imposed fines of £84.2m on…
-

Demystifying the antitrust case against private equity
The heads of the two main US antitrust regulators, Jonathan Kanter (US Department of Justice) and Lina Khan (US Federal Trade Committee), each recently expressed an uneasiness about the lack of antitrust scrutiny of private equity (PE) deals. Mr Kanter told the Financial Times that PE firms aim to “hollow out or roll up an…